Pharmaceuticals
A Passover tribute: Kindness from a Jerusalem neighborhood pharmacy
Every year as Seder approaches, we all look for inspiration in how to make our Seder even richer than the year before.
New immigrant pharmacists face discrimination, lack of gov't support despite professional shortage
EcoSupp listens, learns, and delivers
Israeli health officials call for sanctions on anti-vaxxers as flu morbidity rate rises
Bayer to test new drugs on 3D-printed heart tissue at Tel Aviv University
The new method of testing bypasses many tedious screening methods, making it faster, cheaper and more efficient.
The Lounge March 10, 2020: SuperPharm
A number of Super Pharm’s managers attended the ceremony, and Kupler and Keshet arranged to meet again in the future to discuss continued cooperation.
After turbulent years, Teva CEO Schultz forecasts stability
Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.
86-year-old Copaxone creator has no intention of slowing down
When it comes to being excited by experiments, age is simply not a factor for 86-year-old Prof. Ruth Arnon, co-creator of multiple sclerosis drug Copaxone.
Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv
Researcher Hila Flayev has for years been conducting research on computational models of the coronavirus structure and interactions it can create.
Tufts University to remove Sackler name from buildings and programs
Family has come under fire for their central role in American opioid crisis
Calling Dr. Fischer
Healthcare has always been a part of my home.
![Healthcare and technology [Illustrative]](https://images.jpost.com/image/upload/f_auto,fl_lossy/q_auto/c_fill,g_faces:center,h_194,w_290/432799 "Healthcare and technology [Illustrative]")
Teva shares surge amid hopes of $23 billion opioid claims settlement
Teva stocks also closed up 8.67% on the New York Stock Exchange on Monday amid growing optimism.
Teva proposes $15 billion deal to settle opioid claims
The proposed settlement comes only days ahead of a landmark federal trial in Cleveland, Ohio, against the company and five drug distributors.
Sackler family reaped up to $13 billion from OxyContin maker
The wealthy Sacklers received the money from Purdue during an unspecified time frame, according to court documents and portions of a deposition filed in the drugmaker’s bankruptcy proceedings.
